Avita Medical, Inc. - Common Stock (RCEL)
7.7700
+3.0200 (63.58%)
NASDAQ· Last Trade: Aug 7th, 5:21 PM EDT
Detailed Quote
| Previous Close | 4.750 |
|---|---|
| Open | 6.010 |
| Bid | 7.650 |
| Ask | 7.700 |
| Day's Range | 5.990 - 8.070 |
| 52 Week Range | 3.220 - 7.120 |
| Volume | 7,248,275 |
| Market Cap | 197.97M |
| PE Ratio (TTM) | -6.421 |
| EPS (TTM) | -1.2 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 234,608 |
Chart
About Avita Medical, Inc. - Common Stock (RCEL)
Avita Medical Inc is a regenerative medicine company that focuses on developing products for wound care and tissue repair through its innovative skin regeneration technology. The company's flagship product utilizes a proprietary process that enables the harvesting and application of a small sample of a patient's own skin cells to promote healing for various types of wounds, burns, and other skin injuries. By leveraging the body's natural regenerative capabilities, Avita Medical aims to improve patient outcomes and enhance the recovery process, positioning itself as a leader in advanced therapeutic solutions within the healthcare sector. Read More
News & Press Releases
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.
Via Benzinga · August 7, 2026
What's going on in today's sessionchartmill.com
Via Chartmill · August 7, 2026
Which stocks are gapping on Friday?chartmill.com
Via Chartmill · August 7, 2026
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026.
By AVITA Medical · Via GlobeNewswire · August 7, 2026
Avita Medical (NASDAQ:RCEL) Beats Q2 Estimates and Raises Full-Year Guidancechartmill.com
Via Chartmill · August 6, 2026
AVITA Medical (NASDAQ:RCEL) Q1 2026 Revenue Beat Fails to Offset Wider Loss, Stock Still Rises on Outlookchartmill.com
Via Chartmill · May 14, 2026
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio offerings supported results.
President and Chief Executive Officer Cary Vance said the company’s U.S. RE
Via MarketBeat · August 7, 2026
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the second quarter ended June 30, 2026.
By AVITA Medical · Via GlobeNewswire · August 6, 2026
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2026 financial results after the close of the U.S. financial markets on Thursday, August 6, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 7, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.
By AVITA Medical · Via GlobeNewswire · July 14, 2026
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)
Via Benzinga · July 9, 2026
VALENCIA, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the presentation of new clinical data highlighting the first documented use of RECELL GO in the United Kingdom (U.K.) at the 2026 British Burn Association (BBA) Annual Meeting in Nottingham, U.K.
By AVITA Medical · Via GlobeNewswire · June 18, 2026
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m. Pacific Time (May 21, 2026, at 9:00 a.m. Australian Eastern Standard Time).
By AVITA Medical · Via GlobeNewswire · May 17, 2026
Avita (RCEL) Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 15, 2026
Let's uncover which stocks are experiencing notable gaps during today's session.chartmill.com
Via Chartmill · May 15, 2026
Avita Medical (NASDAQ:RCEL) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand patterns are becoming more consistent.
The regenerative medicine company posted first-quarter rev
Via MarketBeat · May 14, 2026
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the first quarter ended March 31, 2026.
By AVITA Medical · Via GlobeNewswire · May 14, 2026
VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board of Directors has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member.
By AVITA Medical · Via GlobeNewswire · April 30, 2026
VALENCIA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that RECELL GO, its next-generation system for preparing RECELL Spray-On Skin, has received certification from Australia’s Therapeutic Goods Administration (“TGA”) and has been listed on New Zealand’s Web Assisted Notification of Devices (“WAND”) database by Medsafe, enabling commercialization in both markets for burn and acute wound treatment.
By AVITA Medical · Via GlobeNewswire · April 29, 2026
VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.
By AVITA Medical · Via GlobeNewswire · April 23, 2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical Inc. (“AVITA Medical” or the “Company”) (NASDAQ: RCEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · April 21, 2026
VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award by the American Burn Association (ABA). The award, the ABA’s highest honor, recognizes individuals whose enduring contributions have advanced burn care, research, and education. Professor Wood was presented with the award during a ceremony at the ABA 2026 Annual Meeting.
By AVITA Medical · Via GlobeNewswire · April 15, 2026
VALENCIA, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced positive interim results from its Cohealyx-I multi-center study demonstrating a reduction of nearly 20 days in mean time to skin grafting (13.6 days vs 33.2 days benchmark) for patients with full-thickness wounds. The results demonstrated statistical superiority (p<0.001) versus a literature-derived benchmark, based on the lower bound of the 95% confidence interval (28 days). The benchmark was derived from a meta-analysis of published data on leading dermal matrices, representing approximately 900 patients.
By AVITA Medical · Via GlobeNewswire · April 14, 2026
VALENCIA, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced its presence at the 2026 American Burn Association (ABA) Annual Meeting, where new clinical study data on Cohealyx will be presented at a Company-sponsored symposium, alongside investigator-led presentations showcasing real-world clinical experience across the Company’s wound care portfolio.
By AVITA Medical · Via GlobeNewswire · April 7, 2026
VALENCIA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced Cary Vance, Interim CEO, and David O’Toole, CFO, will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.
By AVITA Medical · Via GlobeNewswire · February 23, 2026
VALENCIA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time).
By AVITA Medical · Via GlobeNewswire · February 13, 2026